Full transcript - Legend Biotech Corp (LEGN) Q4 2025: Carlos Santos, Chief Financial Officer, Legend Biotech0: Good day, and welcome to the Legend fourth quarter 2025 earnings call. At this time, all ...

Legend Biotech reported an EPS of -$0.05, missing the forecast slightly. Revenue was $272.33 million, below the expected $274.72 million. The stock rose 2.93% in pre-market trading, indicating ...

Legend Biotech Corp (LEGN) reported robust financial results for Q1 2025, driven by significant sales growth of its flagship product, CARVICTI. The company posted total revenues of $195 million, ...

Legend Biotech Corp (LEGN) reported its second-quarter earnings for 2025, revealing a significant increase in revenue but a larger-than-expected loss per share. The company’s revenue reached 255.06 ...